The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 12, 2020
Filed:
Dec. 11, 2015
Applicant:
Cancer Research Technology Ltd, London, GB;
Inventors:
Frances Rosemary Balkwill, London, GB;
John McCafferty, Cambridge, GB;
Gerard John Graham, Glasgow, GB;
Aneesh Karatt Vellatt, Cambridge, GB;
Peter Slavny, London, GB;
Assignee:
CANCER RESEARCH TECHNOLOGY LIMITED, London, GB;
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/24 (2006.01); A61K 39/00 (2006.01); C12N 15/66 (2006.01);
U.S. Cl.
CPC ...
C07K 16/24 (2013.01); A61K 39/3955 (2013.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C12N 15/66 (2013.01);
Abstract
Anti-CXCL12 antibody molecules and their uses are disclosed, and in particular anti-CXCL12 antibody molecules that are capable of inhibiting a biological activity of CXCL12 in vitro and in vivo and their use for treating CXCL12-mediated disease.